Senator Orrin Hatch (R-UT) recently proposed an amendment to the Hatch-Waxman Act that would significantly upset the availability of petitions for inter partes review (IPR) for generic pharmaceutical companies. Senator Hatch appears to believe that brand pharmaceutical companies deserve patents more than others.
Read More